Nexalin Announces 1-for-30 Reverse Stock Split Approval
TipRanks (Thu, 27-Aug 7:59 AM ET)
Nexalin Technology announces 1-for-30 reverse stock split
Seeking Alpha News (Thu, 27-Aug 7:32 AM ET)
Nexalin Technology Announces Reverse Stock Split
Globe Newswire (Thu, 27-Aug 7:25 AM ET)
Globe Newswire (Tue, 23-Jun 8:30 AM ET)
Globe Newswire (Tue, 16-Jun 9:15 AM ET)
Globe Newswire (Wed, 10-Jun 9:15 AM ET)
Globe Newswire (Thu, 4-Jun 10:00 AM ET)
Market Chameleon (Fri, 22-May 6:34 AM ET)
Nexalin Gains Ground as Federal Backing Advances Deep Brain Neurostimulation Research for Veterans
Market Chameleon (Tue, 24-Feb 5:36 AM ET)
Market Chameleon (Wed, 8-Oct 6:38 AM ET)
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Nexalin Technology trades on the NASDAQ stock market under the symbol NXL.
As of August 28, 2026, NXL stock price declined to $0.25 with 166,891 million shares trading.
NXL has a beta of 2.06, meaning it tends to be more sensitive to market movements. NXL has a correlation of 0.05 to the broad based SPY ETF.
NXL has a market cap of $6.42 million. This is considered a Sub-Micro Cap stock.
Last quarter Nexalin Technology reported $12,161 in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-77,839 and missed earnings estimates by -$.01.
In the last 3 years, NXL traded as high as $4.49 and as low as $.22.
The top ETF exchange traded funds that NXL belongs to (by Net Assets): VXF.
NXL has underperformed the market in the last year with a price return of -72.8% while the SPY ETF gained +19.7%. NXL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -57.2% and -28.6%, respectively, while the SPY returned +2.2% and -0.9%, respectively.
NXL support price is $.24 and resistance is $.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXL shares will trade within this expected range on the day.